SLC5A2 and type 2 diabetes mellitus: On this basis, the 2020 KDIGO guidelines recommend the use of a long-acting GLP-1 receptor agonist in patients with T2DM and CKD who have not achieved adequate glycemic control despite treatment with metformin and an SGLT-2 inhibitor or when the use of metformin and SGLT-2 inhibitors is contraindicated (i.e., in patients with eGFR < 30 mL/min/1.73 m2) [30].